Novalgine (Metamizole Sodium Monohydrate)

Metamizole sodium, the active ingredient in Novalgine, is a pyrazolone presented as an injectable solution for intramuscular and intravenous administration. It provides analgesic and antipyretic effects, making it suitable for the treatment of moderate to severe pain, postoperative discomfort, fever, and colic in adult patients.

GNH USA supplies Novalgine as a licensed, GMP‑certified, GDP‑compliant international pharmaceutical supplier, delivering the product to hospitals, pharmacies, and clinics worldwide through a robust distribution network that meets regulatory requirements across multiple markets and ensures timely, safe delivery.

Novalgine (metamizole sodium) is employed for the management of pain and fever by inhibiting prostaglandin synthesis.

Pain: Provides effective analgesia for acute moderate to severe pain, including musculoskeletal injuries, postoperative discomfort, and visceral pain, improving patient mobility. Fever: Reduces elevated body temperature in febrile conditions, offering rapid antipyretic action that helps prevent complications of high fever. Postoperative pain: Controls pain following surgical procedures, facilitating patient comfort, early mobilization, and smoother postoperative recovery. Colic: Alleviates severe abdominal cramping and discomfort associated with intestinal colic, contributing to faster symptom relief.

Novalgine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Hypotension: transient drop in blood pressure after injection. - Nausea: mild to moderate nausea. - Dizziness: feeling of light‑headedness. - Injection site pain: local discomfort or erythema. - Rash: mild skin irritation. - Headache: mild headache. - Fever: transient low‑grade fever.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells, potentially life‑threatening. - Anaphylaxis: acute allergic reaction with respiratory distress. - Stevens‑Johnson syndrome: severe skin and mucous membrane reaction. - Severe hypotension: prolonged low blood pressure requiring intervention. - Blood dyscrasias: abnormal blood cell counts.

When using Novalgine, clinicians should observe specific precautions to minimize risks.

Assess renal function: adjust use in patients with severe renal impairment. Monitor blood counts: regular CBC testing to detect agranulocytosis early. Avoid in known hypersensitivity: do not administer to patients allergic to pyrazolones. Caution with anticoagulants: increased bleeding risk may occur. Pregnancy and lactation: safety not established; avoid unless benefit outweighs risk. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Novalgine can interact with several medicines; awareness of major and moderate interactions helps ensure safe therapy.

Major Interactions (Avoid): - Concurrent myelotoxic drugs: increased risk of agranulocytosis. - ACE inhibitors: may potentiate hypotensive effects. - Other NSAIDs: additive renal toxicity and gastrointestinal risk.

Moderate Interactions (Monitor Closely): - Anticoagulants: heightened bleeding tendency. - Diuretics: may enhance hypotensive response. - Lithium: possible increase in serum lithium levels.